JP2020524993A - クロンを含む組成物及びその使用 - Google Patents

クロンを含む組成物及びその使用 Download PDF

Info

Publication number
JP2020524993A
JP2020524993A JP2019568601A JP2019568601A JP2020524993A JP 2020524993 A JP2020524993 A JP 2020524993A JP 2019568601 A JP2019568601 A JP 2019568601A JP 2019568601 A JP2019568601 A JP 2019568601A JP 2020524993 A JP2020524993 A JP 2020524993A
Authority
JP
Japan
Prior art keywords
nucleic acid
sequence
synthetic
genetic element
clone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019568601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524993A5 (enExample
Inventor
アバク カーベジアン，
アバク カーベジアン，
エリカ ガブリエル ワインスタイン，
エリカ ガブリエル ワインスタイン，
ニコラス マッカートニー プラギス，
ニコラス マッカートニー プラギス，
ケビン ジェイムズ レボ，
ケビン ジェイムズ レボ，
フェルナンド マーティン ディアズ，
フェルナンド マーティン ディアズ，
ダナンジャイ マニクラール ナワンダル，
ダナンジャイ マニクラール ナワンダル，
Original Assignee
フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド
フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド, フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド filed Critical フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド
Publication of JP2020524993A publication Critical patent/JP2020524993A/ja
Publication of JP2020524993A5 publication Critical patent/JP2020524993A5/ja
Priority to JP2022187239A priority Critical patent/JP2023010961A/ja
Priority to JP2024069618A priority patent/JP2024087003A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019568601A 2017-06-13 2018-06-13 クロンを含む組成物及びその使用 Withdrawn JP2020524993A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022187239A JP2023010961A (ja) 2017-06-13 2022-11-24 クロンを含む組成物及びその使用
JP2024069618A JP2024087003A (ja) 2017-06-13 2024-04-23 クロンを含む組成物及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762518898P 2017-06-13 2017-06-13
US62/518,898 2017-06-13
US201762597387P 2017-12-11 2017-12-11
US62/597,387 2017-12-11
US201862676730P 2018-05-25 2018-05-25
US62/676,730 2018-05-25
PCT/US2018/037379 WO2018232017A1 (en) 2017-06-13 2018-06-13 Compositions comprising curons and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022187239A Division JP2023010961A (ja) 2017-06-13 2022-11-24 クロンを含む組成物及びその使用

Publications (2)

Publication Number Publication Date
JP2020524993A true JP2020524993A (ja) 2020-08-27
JP2020524993A5 JP2020524993A5 (enExample) 2021-07-26

Family

ID=62846247

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019568601A Withdrawn JP2020524993A (ja) 2017-06-13 2018-06-13 クロンを含む組成物及びその使用
JP2022187239A Withdrawn JP2023010961A (ja) 2017-06-13 2022-11-24 クロンを含む組成物及びその使用
JP2024069618A Withdrawn JP2024087003A (ja) 2017-06-13 2024-04-23 クロンを含む組成物及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022187239A Withdrawn JP2023010961A (ja) 2017-06-13 2022-11-24 クロンを含む組成物及びその使用
JP2024069618A Withdrawn JP2024087003A (ja) 2017-06-13 2024-04-23 クロンを含む組成物及びその使用

Country Status (11)

Country Link
US (4) US20200123203A1 (enExample)
EP (1) EP3638797A1 (enExample)
JP (3) JP2020524993A (enExample)
KR (2) KR20250028508A (enExample)
CN (1) CN111108208A (enExample)
AU (2) AU2018285860A1 (enExample)
BR (1) BR112019026226A2 (enExample)
CA (1) CA3066750A1 (enExample)
IL (1) IL271275B2 (enExample)
MX (2) MX2019015018A (enExample)
WO (1) WO2018232017A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024501287A (ja) * 2020-12-23 2024-01-11 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド ＲＮＡを閉じ込めたアネロウイルス（Ａｎｅｌｌｏｖｉｒｕｓ）キャプシドのインビトロアセンブリ

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
US20230048858A1 (en) * 2018-12-12 2023-02-16 Flagship Pioneering Innovations V, Inc. Anellosomes for delivering secreted therapeutic modalities
CA3121528A1 (en) * 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes and methods of use
JP2022513459A (ja) * 2018-12-12 2022-02-08 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド タンパク質代替治療モダリティを送達するためのアネロソーム
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
EP3894567A2 (en) * 2018-12-12 2021-10-20 Flagship Pioneering Innovations V, Inc. Anellosomes for delivering intracellular therapeutic modalities
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
CA3147875A1 (en) 2019-07-19 2021-01-28 Flagship Pioneering Innovations Vi, Llc Recombinase compositions and methods of use
AU2021288320A1 (en) * 2020-06-12 2023-01-19 Flagship Pioneering Innovations V, Inc. Tandem anellovirus constructs
KR20230036109A (ko) * 2020-06-12 2023-03-14 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 바큘로바이러스 발현 시스템
KR20230041686A (ko) * 2020-06-17 2023-03-24 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 아넬로바이러스를 확인 및 특징화하는 방법 및 이의 용도
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
US12018254B2 (en) * 2020-07-27 2024-06-25 Wisconsin Alumni Research Foundation Methods of making unbiased phage libraries
WO2022170195A1 (en) * 2021-02-08 2022-08-11 Flagship Pioneering Innovations V, Inc. Hybrid aav-anellovectors
US20240197823A1 (en) * 2021-02-12 2024-06-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cationic antimicrobial peptides and uses thereof
WO2023069948A1 (en) * 2021-10-18 2023-04-27 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 用於將治療劑遞送至骨之組成物和方法
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525583A (ja) * 1999-02-05 2003-09-02 アボット・ラボラトリーズ Ｔｔウイルスの使用法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR751473A (fr) * 1932-06-01 1933-09-04 Poste d'incendie
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
CN1882693B (zh) 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US7838658B2 (en) 2005-10-20 2010-11-23 Ian Maclachlan siRNA silencing of filovirus gene expression
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
WO2010099510A2 (en) 2009-02-27 2010-09-02 The Administrators Of The Tulane Educational Fund Amino acid-based compounds, their methods of use, and methods of screening
EP2449106B1 (en) 2009-07-01 2015-04-08 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US9676828B2 (en) * 2010-06-23 2017-06-13 Deutsches Krebsforschungszentrum Rearranged TT virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
RU2623161C2 (ru) * 2011-04-15 2017-06-22 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
EP4397759A3 (en) 2012-10-23 2024-10-09 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
MX380562B (es) 2012-12-12 2025-03-12 Broad Inst Inc Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias.
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
WO2015089419A2 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525583A (ja) * 1999-02-05 2003-09-02 アボット・ラボラトリーズ Ｔｔウイルスの使用法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAMADA K. ET AL.: "Transcriptional regulation of TT virus: promoter and enhancer regions in the 1.2-kb noncoding region", VIROLOGY, vol. 321, JPN6023043859, 2004, pages 341 - 348, ISSN: 0005178511 *
SUZUKI T. ET AL.: "Identification of Basal Promoter and Enhancer Elements in an Untranslated Region of the TT Virus Gen", J VIROLOGY, vol. 78, JPN6023043858, 2004, pages 10820 - 10824, ISSN: 0005178512 *
岡本 宏明: "ＴＴウイルスの分子ウイルス学", 日本臨牀, vol. 57, JPN6023043857, 1999, pages 7 - 17, ISSN: 0005178513 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024501287A (ja) * 2020-12-23 2024-01-11 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド ＲＮＡを閉じ込めたアネロウイルス（Ａｎｅｌｌｏｖｉｒｕｓ）キャプシドのインビトロアセンブリ

Also Published As

Publication number Publication date
AU2018285860A1 (en) 2020-01-02
RU2020100074A3 (enExample) 2022-02-08
MX2019015018A (es) 2020-09-10
KR20250028508A (ko) 2025-02-28
US20200123203A1 (en) 2020-04-23
CA3066750A1 (en) 2018-12-20
WO2018232017A1 (en) 2018-12-20
JP2024087003A (ja) 2024-06-28
US20230279423A1 (en) 2023-09-07
BR112019026226A2 (pt) 2020-06-30
IL271275A (en) 2020-01-30
JP2023010961A (ja) 2023-01-20
CN111108208A (zh) 2020-05-05
US20200385757A1 (en) 2020-12-10
MX2023011657A (es) 2023-10-11
US20190211361A1 (en) 2019-07-11
AU2025200497A1 (en) 2025-04-10
EP3638797A1 (en) 2020-04-22
IL271275B1 (en) 2026-04-01
KR20200038236A (ko) 2020-04-10
RU2020100074A (ru) 2021-08-03
IL271275B2 (en) 2026-08-01

Similar Documents

Publication Publication Date Title
US11446344B1 (en) Anellovirus compositions and methods of use
US20230279423A1 (en) Compositions comprising curons and uses thereof
US20220042042A1 (en) Anellosomes and methods of use
JP2024100936A (ja) 分泌治療モダリティを送達するためのアネロソーム
AU2019396516B2 (en) Anellosomes for delivering intracellular therapeutic modalities
JP2024099833A (ja) タンパク質代替治療モダリティを送達するためのアネロソーム
JP2023530277A (ja) バキュロウイルス発現系
WO2021252955A1 (en) Tandem anellovirus constructs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230725

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230814

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231027

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250107